Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15887554 | 0.94 | PTK2 (0.89) | PTK2 | |
| SCHEMBL12149270 | 0.93 | PTK2 (1.00) | PTK2 | |
| SCHEMBL20430649 | 0.93 | PTK2 (0.89) | PTK2 | |
| SCHEMBL12149200 | 0.93 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12149330 | 0.93 | PTK2 (1.00) | PTK2 | |
| SCHEMBL1373737 | 0.92 | PTK2 (0.90) | PTK2 | |
| SCHEMBL12149325 | 0.92 | PTK2 (1.00) | PTK2 | |
| SCHEMBL15887556 | 0.92 | PTK2 (0.89) | PTK2 | |
| SCHEMBL12149331 | 0.91 | PTK2 (1.00) | PTK2 | |
| SCHEMBL15887563 | 0.91 | PTK2 (0.90) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367799-B1 | 2-AMINO-5-TRIFLUOROMETHYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS PTK2 KINASE INHIBITORS | IPHARMA H K LTD (HK) | 2018-08-01 | — | — | EP | disclosed |
| US-8785464-B2 | Pyrimidine derivatives that inhibit FAK/PTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785464-B2 | Pyrimidine derivatives that inhibit FAK/PTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20140038993-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038993-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20110288109-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| WO-2010058030-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288109-A1 | NEW COMPOUNDS | MKI67, CCNA1, CCNT1 | PTK2 1075/4885 |
| US-20140038993-A1 | NEW COMPOUNDS | MKI67, CCNA1, CCNT1 | PTK2 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.